Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study.

Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study.

Item
http://www.wikidata.org/entity/Q52068162
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazinePulsed ultrasound associated with gold nanoparticle gel reduces oxidative stress parameters and expression of pro-inflammatory molecules in an animal model of muscle injury.Measuring performance in clinical rheumatology.Disease activity and joint damage progression in early rheumatoid arthritis: relation to IgG, IgA, and IgM rheumatoid factor.Slow drugs: slow progress? Use of slow acting antirheumatic drugs (SAARDs) in rheumatoid arthritisAntiproliferative effect of gold(I) compound auranofin through inhibition of STAT3 and telomerase activity in MDA-MB 231 human breast cancer cells.The golden age: gold nanoparticles for biomedicine.Disease modifying drugs for rheumatoid arthritis: yesterday's treatment today or today's treatment tomorrow?Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guideCurrent and future management approaches for rheumatoid arthritis.Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritisAuranofin promotes retinoic acid- or dihydroxyvitamin D3-mediated cell differentiation of promyelocytic leukaemia cells by increasing histone acetylation.The journey of rheumatoid arthritis patients: a review of reported lag times from the onset of symptoms.Evaluating drugs in rheumatoid arthritis.Comparison of two approaches to measuring change in health status in rheumatoid arthritis: the Health Assessment Questionnaire (HAQ) and modified HAQ.Early treatment of rheumatoid arthritis: rationale, evidence, and implications.The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells.
P2860

Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study.

Item
http://www.wikidata.org/entity/Q52068162
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh-hant
name
Auranofin improves outcome in ...... lind placebo controlled study.
@en
Auranofin improves outcome in ...... lind placebo controlled study.
@nl
type
label
Auranofin improves outcome in ...... lind placebo controlled study.
@en
Auranofin improves outcome in ...... lind placebo controlled study.
@nl
prefLabel
Auranofin improves outcome in ...... lind placebo controlled study.
@en
Auranofin improves outcome in ...... lind placebo controlled study.
@nl
P1433
P1476
P2093
P304
P31
P407
P433
P478
P577
P698
P921
P1433
P1476
Auranofin improves outcome in ...... lind placebo controlled study.
@en
P2093
P304
P31
P407
P433
P478
P577
P698
P921